New impurity standards
29 Sep 2020
In a previous communication, we informed you about the importance of controlling nitrosamine levels in several products, notably among pharmaceutical compounds. Thanks to the USP, we announce these 6 new nitrosamine impurities available from now in our portfolio:
45-1466674 N-Nitrosodimethylamine (NDMA) (1 mg/mL in methanol)
45-1466652 N-Nitrosodiethylamine (NDEA) (1 mg/mL in methanol)
45-1466663 N-Nitrosodiisopropylamine (NDIPA) (1 mg/mL in methanol)
45-1466641 N-Nitrosodibutylamine (NDBA) (1 mg/mL in methanol)
45-1466685 N-Nitrosoethylisopropylamine (NEIPA) (1 mg/mL in methanol)
45-1466696 N-Nitrosomethylaminobutyric Acid (NMBA) (1 mg/mL in acetonitrile)
These standards are applied mainly in the Pharmaceutical Industry to analyse the following compounds and its derivatives: Alfuzosin, Candesartan, Chlorothiazide, Clopidogrel, Eprosartan, Gabapentin, Irbesartan, Lamotrigine, Levocetirizine, Losartan, Metformin, Olmesartan, Ranitidine, Spectinomycin, Telmisartan, Valsartan and Zolmitriptan. Hence, these new standards may help you in trace level quantification of the target impurities, taking advantage of the LC/MS, GC/MS tests or other suitable techniques and for various test methods.
You may find these new products from now in our broad portfolio. In Cymit Quimica we contribute to the scientific and industrial development of our clients by assisting them in their needs of Fine Chemicals and Biochemicals for R&D and Quality Control.